The SBIO ETF climbed 5% in August, with its performance driven by clinical trial successes and a surge in merger activity within the biotech sector. The fund, which invests in small- and mid-cap firms developing late-stage drug candidates, has achieved a 24.57% return year-to-date and a 75.38% gain over the past year—both figures outpacing broader market benchmarks.
SBIO targets companies valued between $200 million and $5 billion that have at least one drug in Phase II or III trials. This approach allows it to benefit from key regulatory approvals and commercial milestones while meeting the rising demand from major pharmaceutical companies for late-stage assets. As patent protections expire, these industry leaders are increasingly acquiring promising drug candidates to refresh their pipelines.
Since early 2026, six portfolio companies have received acquisition offers, including Day One Biopharmaceuticals, Apellis Pharmaceuticals, and Apogee Therapeutics. This increased merger activity highlights both the urgency to secure innovative treatments and the willingness of buyers to pay higher prices for assets with demonstrated clinical success.
Several key holdings contributed to SBIO’s August performance. Kura Oncology advanced 40.4% after reporting $9.1 million in quarterly revenue for its leukemia treatment, Komzifti, with 115 new patient starts—a 57% increase from the prior quarter. These results indicate early commercial adoption for the drug.
Zai Lab rose 39.35% following the FDA’s Orphan Drug Designation for its experimental cancer therapy, Zocilurtatug pelitecan, alongside steady revenue growth and plans to initiate three key trials before year-end. Meanwhile, Amylyx Pharmaceuticals jumped 66.17% after its Phase III LUCIDITY trial met all primary endpoints for a hypoglycemia treatment, reducing severe low-blood-sugar events by 55% compared to placebo. The company now targets regulatory approval in late 2026, with a potential market launch in 2027.
Even smaller-cap holdings delivered significant gains. Arcturus Therapeutics surged 156% after regaining exclusive global rights to its mRNA vaccine portfolio, including the approved Kostaive COVID-19 vaccine, while securing $12 million in new funding and eliminating $16 million in liabilities. The transaction extended the company’s cash reserves and followed the completion of a Phase II study for a rare metabolic disorder.
Leave a Reply